What if detecting cancer didn’t require surgery, biopsies or invasive procedures?
That future is arriving faster than most people realize. The global noninvasive cancer diagnostics market was valued at $112.8 billion in 2024 and is projected to reach $165.2 billion by 2030 — growing at a 6.6% CAGR.
The technologies driving this growth are transformative.
Liquid biopsy is perhaps the most significant shift. By analyzing circulating tumor DNA (ctDNA) and exosomes from a simple blood draw, clinicians can detect cancer, monitor treatment response and track recurrence — all without invasive tissue biopsies. Companies like Guardant Health, Grail and Freenome are pushing the boundaries of what’s possible.
Multi-cancer early detection (MCED) tests take it further — screening for dozens of cancer types from a single blood sample. This could fundamentally change how population-scale cancer screening works.
AI-enabled diagnostics and digital pathology are making existing screening methods faster and more accurate, while helping address the global shortage of radiologists.
And emerging approaches — urine-based molecular tests, breath-based diagnostics using volatile organic compounds, radiomics, multi-omics platforms — are expanding the diagnostic toolkit beyond anything available a decade ago.
The established players (Roche, Thermo Fisher, Philips, Labcorp, Abbott) are competing alongside fast-moving startups like Lucence, Burning Rock Biotech and PrecisionRNA Biotech.
North America leads with 40.4% of the market.
**Want the complete market analysis?** Download the free overview of our report *Noninvasive Cancer Diagnostics: Technologies and Global Markets* for detailed segmentation, technology assessment and competitive intelligence.
Download the Free Report Overview →
